Key Takeaways

  • Colossal Biosciences is in discussions to raise new capital.
  • The company’s valuation is projected between $20 billion and $30 billion.
  • Colossal has started generating revenue over the past year.
  • Recent partnerships and spin-offs indicate growth in various sectors.

Funding Discussions

Colossal Biosciences, known for its de-extinction efforts, is reportedly in talks to secure new funding at a valuation ranging from $20 billion to $30 billion. This comes approximately 16 months after the company announced its ambitious project to resurrect the dire wolf using genetic material from fossils.

Revenue Generation

Details about the funding round, including the lead investors and the amount being sought, remain unclear. However, reports indicate that Colossal has begun generating revenue, which marks a significant step for the five-year-old startup. Co-founder and CEO Ben Lamm previously mentioned that the company has identified three potential revenue streams.

Partnerships and Spin-offs

Colossal has engaged with the U.S. government and the UAE, which recently invested $60 million in the company. The startup has also launched three spin-off companies: Breaking, focused on plastic breakdown; Form Bio, a computational biology platform that raised $30 million; and Astromech, an AI-driven predictive modeling firm valued at $2 billion as of March.

New Species and Technologies

Operating from a 55,000-square-foot headquarters in Dallas, Colossal continues to explore new applications for its technology. In April, the company added the bluebuck antelope to its list of target species. Additionally, its nonprofit arm, the Colossal Foundation, has partnered with the University of Tasmania to aid in the conservation of Tasmanian devils.

Future Prospects

Lamm has indicated plans to develop artificial animal womb technology, which could have implications for human fertility treatments. This technology is expected to be ready next year. If successful in reintroducing extinct species like the woolly mammoth and dodo bird, Colossal may also generate revenue through biodiversity credits, akin to carbon credits.

Market Context

The fundraising effort aligns with a growing interest in longevity technology, alternative energy, and other deep-tech sectors. Colossal Biosciences did not respond to requests for comment regarding the funding discussions.